Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study

Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes

(2017) Gary H. Lyman   Journal of the National Comprehensive Cancer Network

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Treatment of Older Patients with Mantle-Cell Lymphoma

(2012) H.C. Kluin-Nelemans et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial

(2011) Takashi Watanabe et al.   JOURNAL OF CLINICAL ONCOLOGY

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

(2009) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

(2008) M. Ladetto et al.   BLOOD